CardiaCare announced that it appointed digital health, medical device and remote patient monitoring veteran Ken Nelson as its board chair.
Nelson brings 20 years of medtech experience, including a track record of building successful sales, marketing and commercialization teams.
“Ken brings a wealth of market development, commercialization and sales experience in the cardiac monitoring and cardiac rhythm management space,” said Ofer Halbreich, CEO of CardiaCare.
Halbreigh added that Nelson joins as CardiaCare ramps up multiple clinical trials for its wearable device for AFib treatment.
The clinical-stage digital therapeutic company develops a closed-loop wearable device. It offers a noninvasive treatment for cardiac and other central nervous system-related clinical symptoms. The nerve stimulation system has continuous monitoring and AI-based alert capabilities. It enables complete remote patient management and personalized treatment.
CardiaCare featured among Medical Design & Outsourcing’s 7 cardiology startups you need to know.
“Ken’s prior experience and success scaling cardiac device companies will be invaluable to us as we create global awareness of CardiaCare’s disruptive innovation and build out the infrastructure towards successful commercialization of our technology,” Halbreich said.
About Ken Nelson
Nelson spent just under 10 years in sales and commercial operations leadership roles at Boston Scientific (formerly Guidant). His time there came in the cardiac rhythm management division. Over the past 12 years, Nelson led commercial sales and marketing efforts. He launched wearable technologies in cardiac digital health and remote patient monitoring. His past includes time spent at iRhythm, Biotelemetry (acquired by Philips) and Bardy Diagnostics (acquired by Hillrom).
Most recently, Nelson served as head of digital health, diagnostics and monitoring at Biotronik. He says he feels CardiaCare’s solution can advance patient care for the treatment of AFib.
“I am pleased to join CardiaCare and look forward to working with the management team and the Board, to commercialize the first ever wearable device for closed loop, personalized, atrial fibrillation treatment, powered by artificial intelligence, that can both detect and treat atrial fibrillation non-invasively,” Nelson said. “I’m impressed with the company’s revolutionary technology and the successful engagement with key opinion leaders including Mount Sinai electrophysiologist Dr. Vivek Reddy.
